Core Viewpoint - Teladoc Health (TDOC) has shown a recovery from its lows, but the stock is still under pressure with a significant decline over the longer term [2][3] Stock Performance - Shares increased by 1.37% over the past week and 3.83% over the past month, but are down 21.21% year-to-date and nearly 36% over the past year [2] - The stock is currently priced at $5.57, significantly below its 52-week high of $9.77, and has experienced a five-year decline of 96.85% from a peak of approximately $176.89 [3] Analyst Ratings - The Street consensus target for TDOC is $7.12, with 21 out of 27 analysts rating the stock as a Hold [3] - Barclays has reduced its price target for TDOC to $7 from $8.50, maintaining an Equal Weight rating after discussions with management [4] Revenue and Growth Drivers - Teladoc generated annualized insurance revenue of $40 million in Q4 2025, with a target of $75 million to $90 million for 2026 as BetterHelp transitions to insurance-based delivery [7][8] - International revenue increased by 19% year-over-year to $125 million in Q4 2025, accounting for nearly 24% of total segment revenue for the full year [8] - Adjusted EBITDA improved by 12% to $83.8 million in Q4, and the company generated $167 million in free cash flow for the full year 2025 [8] Business Transition - BetterHelp's revenue fell by 7% year-over-year in Q4 2025, with guidance for a further decline of 0.5% to 7.0% in 2026 as the segment shifts towards insurance-based delivery [5][6] - The company's recovery hinges on growing BetterHelp's insurance business faster than the decline in its direct-pay business, with a market capitalization target of approximately $1.25 billion to reach the Barclays price target by the end of 2026 [7]

Core Viewpoint - Mangoceuticals, Inc. has filed a civil lawsuit against Clarity Ventures, Inc. seeking damages exceeding $73 million due to alleged failures in delivering a functional ERP and eCommerce platform [2][3]. Group 1: Lawsuit Details - The lawsuit was filed in Texas state court and seeks damages over $73 million, excluding interest, costs, and attorneys' fees [2]. - The company claims that Clarity Ventures did not deliver a fully functional, HIPAA-compliant ERP and eCommerce platform as agreed [2]. - Clarity Ventures has denied the allegations and filed counterclaims regarding unpaid invoices, which the company disputes, asserting all payments were made in full prior to disengagement [3]. Group 2: Company Response and Developments - Following the issues with Clarity, the company independently developed a new proprietary telehealth and eCommerce platform that supports its operations without relying on Clarity's technology [4]. - The management believes that the new platform has led to improvements in customer acquisition, order fulfillment, and overall operating performance [4]. Group 3: Company Overview - Mangoceuticals, Inc. focuses on developing health and wellness products through a secure telemedicine platform, offering pharmaceutical-based products for men's health, including treatments for erectile dysfunction, hair growth, hormone replacement therapies, and weight management [6].

Group 1 - The CEO of the company, Charles Divita, has a long history with Teladoc, having previously been an executive at a large health plan [1] - In 2018, the importance of Teladoc was recognized in discussions with brokers, highlighting its relevance to customer bases [1] - The company decided to roll out Teladoc services to all commercial members by the fall of 2019, prior to the pandemic [2] Group 2 - The pandemic significantly impacted the company's member engagement with Teladoc services [2]

As filed with the U.S. Securities and Exchange Commission on March 10, 2026. Registration No. 333-291959 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Blue Water Acquisition Corp. IV (203) 489-2110 (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) Joseph Hernandez 15 E. Putnam Avenue Suite 363 Greenwich, CT 06830 (203) 489-2110 (Exa ...

Core Viewpoint - Deutsche Bank upgraded Teladoc Health to Buy from Hold with a price target of $11, citing attractive valuation and a credible turnaround strategy for the BetterHelp segment [1] Group 1: Valuation and Market Position - Teladoc shares are currently trading at approximately 4.2 times Deutsche Bank's 2026 EBITDA estimate, one of the lowest multiples in the firm's coverage universe [2] - Such low valuations are typically associated with companies facing existential risks, which Deutsche Bank believes does not apply to Teladoc's expanding Integrated Care segment [2] Group 2: BetterHelp Segment Strategy - The BetterHelp business has been experiencing declines, but management has introduced a strategy to stabilize and grow the segment by shifting from a cash-pay model to insurance-covered therapy services [3] - Demand for insured therapy services is increasing, as evidenced by Universal Health Services' recent acquisition of Talkspace, a competitor in the insured therapy market [4] Group 3: Potential for Value Unlocking - The acquisition of Talkspace suggests a potential upside for Teladoc's current share price, indicating a path for unlocking value in the market [4]

Upgrades - TD Cowen upgraded Rivian (RIVN) to Buy from Hold with a price target of $20, up from $17, based on a detailed R2 demand analysis indicating full scale R2 demand at 212,000-335,000 units, suggesting upside to consensus forecasts for 2027 [2] - Morgan Stanley upgraded CrowdStrike (CRWV) to Overweight from Equal Weight with a price target of $510, up from $487, believing CrowdStrike is best positioned in security to outperform in the coming years, stating the platform is "most able to gain share" [2] - Deutsche Bank upgraded Teladoc (TDOC) to Buy from Hold with an $11 price target, viewing the stock's valuation as "compelling" at current share levels [2] - BofA upgraded Hims & Hers (HIMS) to Neutral from Underperform with a price target of $23, up from $12.50, noting a positive development as Novo Nordisk dropped its lawsuit, removing litigation and related credit risk [2] - Citi also upgraded Hims & Hers to Neutral from Sell with a price target of $24, up from $13.25 [2] - Rothschild & Co Redburn upgraded Intuit (INTU) to Buy from Neutral with a price target of $700, up from $670, indicating 46% upside from current levels, highlighting the resilience of QuickBooks and TurboTax applications to AI disruption risk in the enterprise software sector [2]

Core Viewpoint - Momentum investing focuses on "buying high and selling higher" rather than the traditional "buying low and selling high" approach, aiming for quicker profits [1] Group 1: Momentum Investing Characteristics - Fast-moving trending stocks can be difficult to enter at the right time, as they may lose momentum if future growth does not justify their high valuations [2] - Investing in bargain stocks that have recently shown price momentum can be a safer strategy, with tools like the Zacks Momentum Style Score aiding in identifying such stocks [3] Group 2: American Well Corporation (AMWL) Analysis - AMWL has shown significant price momentum, with a four-week price change of 23%, indicating growing investor interest [4] - The stock has gained 18.4% over the past 12 weeks and has a beta of 1.34, suggesting it moves 34% more than the market [5] - AMWL has a Momentum Score of B, indicating a favorable time to invest based on momentum [6] Group 3: Earnings Estimates and Valuation - An upward trend in earnings estimate revisions has contributed to AMWL earning a Zacks Rank 2 (Buy), which is associated with strong momentum effects [7] - AMWL is trading at a Price-to-Sales ratio of 0.36, indicating it is relatively cheap, as investors pay only 36 cents for each dollar of sales [7] Group 4: Additional Investment Opportunities - Besides AMWL, there are other stocks that meet the criteria of the 'Fast-Paced Momentum at a Bargain' screen, suggesting further investment opportunities [8] - Various Zacks Premium Screens are available to help identify winning stock picks based on different investing styles [9]

Core Insights - LifeMD, Inc. is a leading provider of virtual primary care services, offering telemedicine and access to laboratory and pharmacy services across more than 200 conditions [1][2] - The company will participate in several investor conferences in March 2026, including the Mizuho Securities Healthcare Technology Conference and the KeyBanc Capital Markets Healthcare Forum [2] Company Overview - LifeMD provides a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, and a state-of-the-art affiliated pharmacy [1] - The company focuses on various health areas, including primary care, men's and women's health, weight management, and hormone therapy [1] Upcoming Events - Management will hold virtual one-on-one meetings with investors on March 5 during the Mizuho Securities Healthcare Technology Conference [2] - On March 17-18, management will participate in a virtual fireside chat and a panel discussion at the KeyBanc Capital Markets Healthcare Forum [2]

Core Viewpoint - The latest quarterly results for Hims and Hers show mixed performance, with a notable focus on the impact of GLP1-related issues and a shift back to core business areas [2][4][5]. Financial Performance - Earnings per share (EPS) for the quarter were reported at 8 cents, which is double the street's expectations [2]. - Revenue for Q4 was approximately $617 million, slightly below the expected $619 million, with forward guidance for Q1 projected between $600 million to $625 million, lower than Wall Street's expectation of $654 million [3][4]. Business Strategy - Hims and Hers is pivoting away from a heavy reliance on GLP1 products, emphasizing growth in their sexual health and dermatology segments, which grew over 30% [5]. - The company has a subscriber base of 2.5 million, with only a small portion using GLP1s, indicating a broader business model beyond this product line [5]. Market Challenges - The company faces legal and regulatory challenges, particularly related to a lawsuit from Nova Nordisk, which may limit stock valuation in the near term [8]. - There is a noted decline in investor enthusiasm for Hims and Hers, primarily due to diminishing excitement around GLP1 products and pricing pressures [9]. Future Outlook - The addressable market for GLP1s is expected to grow, but Hims and Hers' lack of access to these products is seen as a significant disadvantage [10][12]. - The company is focusing on a personalized medicine strategy, which includes lab tests to tailor medications, indicating potential for growth despite current challenges [14].

Financial Performance - Teladoc Health reported a quarterly loss of 14 cents per share, which was better than market estimates of a loss of 18 cents per share [1] - The company's sales for the quarter reached $642.269 million, exceeding estimates of $635.235 million [1] - For FY2026, Teladoc Health anticipates a GAAP loss in the range of $(1.10) to $(0.70), compared to market estimates of $(0.76) [1] - The company expects sales between $2.470 billion and $2.587 billion, surpassing estimates of $2.548 billion [1] Strategic Outlook - The CEO of Teladoc Health, Chuck Divita, expressed optimism about the company's progress in 2025, highlighting that consolidated revenue and adjusted EBITDA were above the midpoint of guidance ranges for the fourth quarter [2] - The company has made advancements in its product portfolio and innovation across Integrated Care and BetterHelp, positioning itself for continued momentum in 2026 [2] Market Reaction - Following the earnings report, Teladoc Health shares increased by 13.5%, trading at $5.28 [3]